Sumithira Vasu is Professor at The Ohio State University. OpenAlex indexes 371 publications with 4,198 citations (h-index 33); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 27 Oct 2026
Sumithira Vasu, M.D., is Professor at The Ohio State University. The public record shows 371 publications with 4,198 citations (h-index 33), centered on Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Renal Transplantation Outcomes and Treatments. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 5 companies, 3 NIH-funded awards (2017–2026).
- Most recent indexed publication: 2026 · Blood cancer discovery
- Top research focus: Hematopoietic Stem Cell Transplantation
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 27 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 81.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 26 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Sponsor: Ohio State University Comprehensive Cancer Center
- Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
Sponsor: Children's Hospital Medical Center, Cincinnati
Industry payments
Updated 26 Oct 2026
5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20253 payments
- National Marrow Donor ProgramProgram year20255 payments
- National Marrow Donor ProgramProgram year20243 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor63.5%Jakafi86%Tasigna14%Part D<11 patientsSelective immunosuppressants12.4%Rezurock100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 26 Oct 2026
3 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:
- Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies
Ohio State University
FY2026$609,273R01CA276374 - BMT Core- The Ohio State University blood and marrow transplant research consortium
Ohio State University
FY2026$219,365UG1HL109322 - Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies
Ohio State University
FY2025$609,273R01CA276374
Congress activity
Updated 26 Oct 2026
79 congress contributions (2015–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 26 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22.
Blood cancer discovery
Clinical Trial2026 - TA-TMA and GVHD are distinct consequences of endothelial injury: a MIDAS consortium study.
Blood advances
Article2026 - Biallelic germline MBD4 mutations predispose to colorectal polyposis, hypermutated AML, and schwannomas.
Familial cancer
Case Report2026
Most-cited works
by citation count (OpenAlex)- 01Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell NeoplasmArticle437 citations2019
- 02Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyArticle157 citations2017
- 04
- 05
Network
Updated 26 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 26 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/sumithira-vasu-md
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
healthtree.org/aml/community/directory/oh/the-ohio-state-university-comprehensive-cancer-center-columbus-oh/sumithira-vasu
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 26 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ohiostate.elsevierpure.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Jennifer Woyach, MD
The Ohio State University
Yuchi Han, MD
The Ohio State University
Uma Borate, MD
The Ohio State University
Sooyoung Kim
The Ohio State University
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center